Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia-Reference-Cited by-同舟云学术

Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia

Published:2018-12-01 Issue:12 Volume:172 Page:1161
ISSN:2168-6203
Container-title:JAMA Pediatrics
language:en
Short-container-title:JAMA Pediatr

Author:

Whittington Melanie D.¹,McQueen R. Brett¹,Ollendorf Daniel A.²,Kumar Varun M.²,Chapman Richard H.²,Tice Jeffrey A.³,Pearson Steven D.²,Campbell Jonathan D.¹

Affiliation:

1. Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora

2. The Institute for Clinical and Economic Review, Boston, Massachusetts

3. Department of Medicine, University of California, San Francisco

Publisher

American Medical Association (AMA)

Subject

Pediatrics, Perinatology and Child Health

Reference32 articles.

1. Childhood and adolescent cancer statistics, 2014.;Ward;CA Cancer J Clin,2014

2. Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: findings from the CONCORD-2 study.;Tai;Cancer,2017

3. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.;Hamlin;Blood,2003

4. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.;Vose;J Clin Oncol,2001

5. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin’s disease and non-Hodgkin’s lymphoma.;Mink;Oncologist,2001

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review;Value in Health;2024-08

2. A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies;Human Gene Therapy;2024-06-01

3. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study;Applied Health Economics and Health Policy;2024-04-29

4. The fulfilled promise and unmet potential of umbilical cord blood;Current Opinion in Hematology;2024-04-05

5. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy;Value in Health;2024-04